Zacks Investment Research lowered shares of Aeterna Zentaris Inc. (NASDAQ:AEZS) from a buy rating to a hold rating in a research note released on Tuesday morning.
According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
A number of other brokerages also recently issued reports on AEZS. Canaccord Genuity reiterated a buy rating and issued a $9.00 price objective on shares of Aeterna Zentaris in a research report on Tuesday, August 23rd. Maxim Group reiterated a buy rating and issued a $11.00 price objective on shares of Aeterna Zentaris in a research report on Tuesday, July 5th. Finally, HC Wainwright restated a buy rating on shares of Aeterna Zentaris in a research report on Thursday, August 11th.
Shares of Aeterna Zentaris (NASDAQ:AEZS) traded up 11.671% during trading on Tuesday, hitting $3.875. The stock had a trading volume of 813,280 shares. The firm’s 50 day moving average is $3.51 and its 200 day moving average is $3.54. The company’s market cap is $38.51 million. Aeterna Zentaris has a 1-year low of $2.60 and a 1-year high of $15.70.
Aeterna Zentaris (NASDAQ:AEZS) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.11. Aeterna Zentaris had a negative return on equity of 241.78% and a negative net margin of 5,871.45%. Equities research analysts anticipate that Aeterna Zentaris will post ($2.61) EPS for the current fiscal year.
A hedge fund recently raised its stake in Aeterna Zentaris stock. Renaissance Technologies LLC boosted its position in shares of Aeterna Zentaris Inc. (NASDAQ:AEZS) by 5.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 516,833 shares of the biopharmaceutical company’s stock after buying an additional 29,000 shares during the period. Renaissance Technologies LLC owned 8.17% of Aeterna Zentaris worth $1,716,000 as of its most recent SEC filing. 8.28% of the stock is owned by hedge funds and other institutional investors.
About Aeterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.